The Uromigos
Advertisement
Daniel Goldstein returns to the podcast to discuss dosing changes in drugs such as nivolumab and pembrolizumab.
Dr. Galsky describes the OS signal data from CheckMate-274 on adjuvant nivolumab for muscle-invasive bladder cancer.
Dr. Matt Galsky, Brian, and Tom discuss the IMvigor011 trial data that was presented at EAU 2024.
Michiel Van der Heijdan explores the role of radiotherapy and other neoadjuvant combinations for MIBC.
Dr. Galsky discusses his phase 2 study evaluating the effects of gem/cis/nivo followed by nivolumab in responders.
FDA Deputy Oncology Director Dan Suzman describes approaches to oncology trials in the GU setting.
Dr. Tanya Dorff discusses her work on a phase 1 study investigating acapatamab for advanced prostate cancer.
Michael Lattanzi, MD, joins the podcast to discuss treatment plans and research in the community oncology setting.
The Uromigos discuss adjuvant therapy in kidney and bladder cancer trials including KEYNOTE-564.
Vania Wisdom, Senior Executive Editor at The Lancet, discusses cancer treatment and research in developing countries.
Dr. McDermott discusses the similarities between current melanoma trials and kidney cancer treatments.
Dr. Dana Rathkopf describes the phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer.
Reviewing the top presentations from ASCO GU 2024, including the phase III GETUG-AFU-18 study, CONTACT-02, and more.
Dr. Agarwal discusses the CONTACT-02 trial that analyzed the use of cabozantinib in combination with atezolizumab for mCRPC.
Dr. Bergerot describes her modifications of existing quality of life models, and Tom explains LITESPARK-005's QoL data.
Dr. Pedro Barata gives an overview of the CheckMate 914 trial on adjuvant nivolumab plus ipilimumab for localized RCC.
Andrea Apolo, MD, discusses the phase III AMBASSADOR study that investigated adjuvant pembrolizumab against observation.
Dr. Kim Chi discusses the BRCAAway and CONTACT-02 trials presented at ASCO GU 2024.
Dr. Himisha Beltran, describes the activity of novel agent HPN328 in neuroendocrine prostate cancer.
Neeraj Agarwal describes the results of the phase III CONTACT-02 trial on cabozantinib plus atezolizumab in prostate cancer.
...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.